Publication | Open Access

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Hematological MalignancyLymphoid NeoplasiaCodox-m/ivac RegimenMedicineImmunologyPathologyLiposomal DoxorubicinHigh-dose RituximabImmunotherapyOncologyRadiation Oncology